Gemcitabine (2',2'-difluorodeoxycytidine) 是一種 fluorine- substituted deoxycytidine 的相似物，具有廣效的抗腫瘤活性。 此成分會快速地被 cytidine deaminase 脫氨形成不具活性之代謝物 2',2'-difluorodeoxyuridine (dFdU)。為了提高 gemcitabine 的生體可用率及口服後 gemcitabine 的安定性，因華應用 OralPAS® 技術於 gemcitabine 製備獨特的口服配方。OralPAS® 能增加藥物於賦形劑或腸胃道中之溶解度以提高生體可用率。這些特性使藥物能夠更快地從奈米分子中釋放出來，且未來可針對獨特的腸胃生理及病患餐前/後期設計釋放效果。近期，已完成部分體外/體內試驗 (例：大鼠與狗之先導試驗)，試驗成果皆符合目標。

相關研究發表

• 2009 AAPS_Oral Administration of Gemcitabine (INNO-D07001) in Beagle Dogs_ Preliminary Pharmacokinetic Evaluation of Gemcitabine and Its metabolite
• 2010 AAPS_ In-vitro and in-vivo Evaluation of Oral SMEDDS (Self-Microemulsifying Drug Delivery System) Formulation
• 2011 AAPS_In vitro and in vivo Evaluation of a Novel Oral SMEDDS (Self-Microemulsifying Drug Delivery System) Formulation
• 2011 AAPS_The anti-proliferative efficacy of an OralPAS gemcitabine Formulation
• 2012 AAPS_Toxicokinetic Study of an OralPAS Gemcitabine
• 2013 AAPS_ Drug Distribution of [14C] Gemcitabine Using Quantitative Whole-Body Autoradiography after a Single Oral and Intravenous Bolus Doses Administration to Male Nu/Nu Mice
• 2014 ASCO_Phase I, Dose-escalation Study of the Investigational Drug D07001_F4, and Oral Formulation of Gemcitabine HCl, in Patients(pts) with Advanced Solid Tumors
• 2014 EORTC-NCI-AACR_ Phase I, Dose-escalation Study of the Investigational Drug D07001_F4, and Oral Formulation of Gemcitabine HCl, in Patients(pts) with Advanced Solid Tumors

C08001是一種治療高血壓、心衰竭、左心室功能不全伴隨心肌梗塞的藥物。C08001的活性物質為低水溶性，不利於腸胃道釋放、吸收。此活性物質之既有速放劑型的給藥頻率是一天兩次，C08001增加了此活性物質之溶解度並被改良成為一天一次給藥的緩釋錠劑。